Sugi Predict

Sugi Predict / Compounds / SCHEMBL576463

SCHEMBL576463

SCHEMBL576463

C[C@@H](c1ccccc1)N1CC(CO)CC1=O

nearest known ligand 0.63

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.63
▸ MAPK1 P28482 1/20 0.51
▸ BRD4 O60885 1/20 0.46
▸ GRM5 P41594 1/20 0.41
▸ HSD11B1 P28845 2/20 0.40
▸ HSD17B2 P37059 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ P2RX3 P56373 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL576462 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL523900 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL8207326 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL27902911 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL5626616 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL4529849 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL523899 1.00 KMT2A (0.63) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL9987097 0.90 KMT2A (0.53) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL14405525 0.89 KMT2A (0.60) KMT2AMAPK1BRD4GRM5HSD11B1
SCHEMBL20306298 0.87 KMT2A (0.48) KMT2AMAPK1BRD4HSD11B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2017-06-01 — — US disclosed
US-20160002221-A1 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LTD (CN) 2016-01-07 — — US disclosed
US-20160002221-A1 Substituted Pyridopyrazines as Syk Inhibitors HUTCHISON MEDIPHARMA LTD (CN) 2016-01-07 — — US disclosed
CN-104812753-A Substituted pyridopyrazines as syk inhibitors HUTCHISON MEDIPHARMA LTD 2015-07-29 — — CN disclosed
WO-2014086316-A1 SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-06-12 — — WO disclosed
US-8212072-B2 Process for the preparation of pregabalin Divi's Laboratories, Ltd. (IN) 2012-07-03 — — US disclosed
US-20120041212-A1 PROCESS FOR THE PREPARATION OF PREGABALIN DIVI'S LABORATORIES LIMITED (IN) 2012-02-16 — — US disclosed
EP-2418194-A1 Process for the preparation of pregabalin Divi's Laboratories Limited (IN) 2012-02-15 — — EP disclosed
US-6642398-B2 Improving drug qualities such as bioavailability and stability WARNER-LAMBERT COMPANY 2003-11-04 — — US disclosed
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids BELLIOTTI THOMAS RICHARD (US) 2003-09-25 — — US disclosed
US-20030176504-A1 Method of treating tinnitus DOOLEY DAVID JAMES (US) 2003-09-18 — — US disclosed
US-6620829-B2 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt WARNER-LAMBERT COMPANY 2003-09-16 — — US disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 — — US disclosed
CN-1355784-A Mono-and disubstituted 3-propyl-gamma-aminobutyric acids WARNER LAMBERT CO (US) 2002-06-26 — — CN disclosed
US-20020072533-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2002-06-13 — — US disclosed
EP-1199072-A2 Method of treating cartilage damage WARNER-LAMBERT COMPANY (US) 2002-04-24 — — EP disclosed
EP-1192125-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076958-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041212-A1 PROCESS FOR THE PREPARATION OF PREGABALIN GABRA5, GABRA6, GABRE KMT2A 2233/4885MAPK1 3216/4885BRD4 4372/4885
US-20030176504-A1 Method of treating tinnitus ADRA2A, ADRA1A, ADRA1D KMT2A 823/4885MAPK1 2302/4885BRD4 1303/4885
US-20020072533-A1 Method of treating cartilage damage COL2A1, COL1A1, GABRB1 KMT2A 3421/4885MAPK1 3047/4885BRD4 1292/4885
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 KMT2A 3440/4885MAPK1 544/4885BRD4 1051/4885
US-20160002221-A1 Substituted Pyridopyrazines as Syk Inhibitors SYK, BTK, LYN KMT2A 597/4885MAPK1 935/4885BRD4 967/4885
US-20170152258-A9 Substituted Pyridopyrazines as Syk Inhibitors SYK, BTK, LYN KMT2A 597/4885MAPK1 935/4885BRD4 967/4885
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids GABRB1, GABRA1, GABRB3 KMT2A 1992/4885MAPK1 4187/4885BRD4 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.